MS drug Tysabri should return: panel

March 8, 2006

GAITHERSBURG, Maryland (Reuters) – Biogen Idec and Elan Corp.’s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday.

Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection. Two of them died.

Source: reuters

comments powered by Disqus